Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products

Feb 1, 2021, 00:00
10.1016/j.jval.2020.10.006
https://www.valueinhealthjournal.com/article/S1098-3015(20)34449-1/fulltext
Title : Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)34449-1&doi=10.1016/j.jval.2020.10.006
First page : 268
Section Title : POLICY PERSPECTIVE
Open access? : No
Section Order : 268

Objectives

Orphan medicinal products (OMPs) often receive market authorization under conditions imposed by regulators for ongoing postauthorization surveillance (PAS) to answer questions that remain at the time of market entry. This surveillance may be provided through industry-funded registries (IFRs). Nevertheless, data in these registries may not be of sufficient quality to answer these questions and may not always be accessible for regulatory review. We propose that a mandatory independent registry is an efficient and cost-effective tool for PAS for OMPs.

Methods

Using data from the Canadian Fabry Disease Initiative, we reviewed costs per unique patient from sites participating in both the independent national registry and IFRs for Fabry disease and compared data completeness from the Canadian Fabry Disease Initiative to that in published documents from IFRs.

Results

The costs of data collection through the independent registry were 17% to 36% (depending on site) lower than costs to collect data in the IFRs, and completeness of data collected through the independent registry was higher than that through the IFRs. Data from the independent registry were reviewed annually to guide indications for publicly funded Fabry disease therapy. Even when enrollment ceased to be a requirement to receive therapy, 77% of patients continued to enroll in the registry, suggesting the structure was acceptable to patients.

Conclusions

Independent registries are cost-effective and efficient tools and should be mandated by regulatory agencies as the preferred tool for PAS for OMPs. Countries with publicly funded health systems should consider investment in registry infrastructure for OMPs.

Categories :
  • Approval & Labeling
  • Formulary Development
  • Health Policy & Regulatory
  • Health Service Delivery & Process of Care
  • Post Marketing Studies
  • Rare & Orphan Diseases
  • Registries
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • Fabry disease
  • orphan medicinal products
  • postauthorization surveillance
  • registry
Regions :
ViH Article Tags :